Filing Flows › Orchestra BioMed Holdings (OBIO) › Recalls, complaints & regulation
Orchestra BioMed Holdings (OBIO): clinical trials
Orchestra BioMed Holdings (OBIO) beyond its filings: 2 active clinical trials.
Orchestra BioMed Holdings' latest quarter
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Orchestra BioMed Holdings have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.